Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / COM
-
Number of holders
-
75
-
Total 13F shares, excl. options
-
13.9M
-
Shares change
-
+2.01M
-
Total reported value, excl. options
-
$30.9M
-
Value change
-
+$4.62M
-
Put/Call ratio
-
4
-
Number of buys
-
32
-
Number of sells
-
-24
-
Price
-
$2.22
Significant Holders of Protalix BioTherapeutics, Inc. - COM (PLX) as of Q3 2025
83 filings reported holding PLX - Protalix BioTherapeutics, Inc. - COM as of Q3 2025.
Protalix BioTherapeutics, Inc. - COM (PLX) has 75 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 13.9M shares
.
Largest 10 shareholders include BlackRock, Inc. (3.55M shares), Opaleye Management Inc. (2.58M shares), RENAISSANCE TECHNOLOGIES LLC (1.32M shares), NORTHERN TRUST CORP (902K shares), GEODE CAPITAL MANAGEMENT, LLC (820K shares), Stratos Wealth Partners, LTD. (500K shares), STATE STREET CORP (499K shares), VANGUARD GROUP INC (464K shares), Connor, Clark & Lunn Investment Management Ltd. (400K shares), and UBS Group AG (190K shares).
This table shows the top 75 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.